[8-K] Tourmaline Bio, Inc. Reports Material Event
Tourmaline Bio, Inc. furnished a Current Report on Form 8-K stating it issued a press release announcing business highlights and financial results for the quarter ended June 30, 2025. The press release is attached as Exhibit 99.1 and an Inline XBRL cover page is included as Exhibit 104. The company states this information is being furnished, not filed, so it is not subject to Section 18 liabilities and is not incorporated by reference into other filings unless expressly stated.
The 8-K contains no numerical financial data or operational detail itself; readers must consult Exhibit 99.1 for the actual figures and narrative. The registrant's common stock trades under TRML on the Nasdaq Global Select Market and no other material transactions or financial tables are included in this filing.
Tourmaline Bio, Inc. ha presentato un Current Report on Form 8-K in cui comunica di aver diffuso un comunicato stampa con i principali eventi aziendali e i risultati finanziari relativi al trimestre chiuso il 30 giugno 2025. Il comunicato 猫 allegato come Exhibit 99.1 e una pagina di copertina Inline XBRL 猫 inclusa come Exhibit 104. La societ脿 precisa che queste informazioni sono fornite, non depositate, pertanto non sono soggette alle responsabilit脿 previste dalla Sezione 18 e non vengono incorporate per riferimento in altri documenti salvo esplicita indicazione.
L'8-K in s茅 non contiene dati finanziari numerici n茅 dettagli operativi; per i valori e la descrizione occorre consultare l'Exhibit 99.1. Le azioni ordinarie del registrante sono negoziate con il simbolo TRML sul Nasdaq Global Select Market e nel presente documento non sono incluse altre operazioni rilevanti o tabelle finanziarie.
Tourmaline Bio, Inc. present贸 un Current Report on Form 8-K en el que anuncia la emisi贸n de un comunicado de prensa con los aspectos m谩s relevantes del negocio y los resultados financieros del trimestre concluido el 30 de junio de 2025. El comunicado se adjunta como Exhibit 99.1 y se incluye una portada Inline XBRL como Exhibit 104. La compa帽铆a indica que esta informaci贸n se proporciona, no se presenta, por lo que no est谩 sujeta a las responsabilidades de la Secci贸n 18 y no se incorpora por referencia en otros documentos salvo que se indique expresamente.
El 8-K en s铆 no contiene cifras num茅ricas ni detalles operativos; los lectores deben consultar el Exhibit 99.1 para los datos y la narrativa. Las acciones ordinarias del registrante cotizan bajo el s铆mbolo TRML en el Nasdaq Global Select Market y en este informe no se incluyen otras transacciones materiales ni tablas financieras.
Tourmaline Bio, Inc.電� Current Report on Form 8-K毳� 鞝滌稖頃橃棳 2025雲� 6鞗� 30鞚茧 膦呺霅� 攵勱赴鞚� 欤检殧 靷梾 雮挫毄 氚� 鞛 瓴瓣臣毳� 鞎岆Μ電� 氤措弰鞛愲毳� 氚滍憸頄堧嫟瓿� 氚濏様鞀惦媹雼�. 氤措弰鞛愲電� Exhibit 99.1搿� 觳秬霅橃柎 鞛堨溂氅� Inline XBRL 響滌電� Exhibit 104搿� 韽暔霅橃柎 鞛堨姷雼堧嫟. 須岇偓電� 鞚� 鞝曤炒臧� 鞝滌稖霅� 瓴冹澊 鞎勲媹霛� 鞝滉车霅� 瓴�鞚措澕瓿� 氇呾嫓頃橃棳 靹轨厴 18鞐� 霐半ジ 毂呾瀯鞚� 雽�靸侅澊 鞎勲媹氅�, 氇呾嫓鞝侅溂搿� 鞏戈笁霅橃 鞎婋姅 頃� 雼るジ 靹滊鞐� 彀胳“搿� 韱淀暕霅橃 鞎婋姅雼り碃 頃╇媹雼�.
頃措嫻 8-K 鞛愳泊鞐愲姅 靾橃箻鞝� 鞛 雿办澊韯半倶 鞖挫榿 靹鸽秬靷暛鞚� 韽暔霅橃柎 鞛堨 鞎婌溂氙�搿� 鞁れ牅 靾橃箻鞕� 靹る獏鞚� Exhibit 99.1鞚� 頇曥澑頃挫暭 頃╇媹雼�. 霌彪須岇偓鞚� 氤错喌欤茧姅 TRML鞚措澕電� 鞁臣搿� Nasdaq Global Select Market鞐� 靸侅灔霅橃柎 鞛堨溂氅�, 鞚� 鞝滌稖靹滊鞐愲姅 旮绊儉 欷戩殧頃� 瓯半灅雮� 鞛響滉皜 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟.
Tourmaline Bio, Inc. a fourni un Current Report on Form 8-K indiquant qu'elle a publi茅 un communiqu茅 de presse pr茅sentant les faits marquants et les r茅sultats financiers du trimestre clos le 30 juin 2025. Le communiqu茅 est joint en tant que Exhibit 99.1 et une page de couverture Inline XBRL est incluse en tant que Exhibit 104. La soci茅t茅 pr茅cise que ces informations sont fournies, non d茅pos茅es, elles ne sont donc pas soumises aux responsabilit茅s pr茅vues par la Section 18 et ne sont pas incorpor茅es par r茅f茅rence dans d'autres documents, sauf indication expresse.
Le 8-K lui-m锚me ne contient pas de donn茅es chiffr茅es ni de d茅tails op茅rationnels聽; il convient de consulter l'Exhibit 99.1 pour les chiffres et le commentaire. Les actions ordinaires de l'茅metteur se n茅gocient sous le symbole TRML sur le Nasdaq Global Select Market et aucun autre acte significatif ni aucune table financi猫re n'est inclus dans ce d茅p么t.
Tourmaline Bio, Inc. hat einen Current Report on Form 8-K eingereicht und darin eine Pressemitteilung mit Gesch盲ftshighlights und Finanzzahlen f眉r das am 30. Juni 2025 endende Quartal ver枚ffentlicht. Die Pressemitteilung ist als Exhibit 99.1 beigef眉gt, eine Inline-XBRL-Titelseite ist als Exhibit 104 enthalten. Das Unternehmen stellt klar, dass diese Informationen bereitgestellt, nicht eingereicht werden, weshalb sie nicht den Haftungsregelungen nach Abschnitt 18 unterliegen und nicht ohne ausdr眉ckliche Angabe in andere Einreichungen 眉bernommen werden.
Der 8-K selbst enth盲lt keine numerischen Finanzdaten oder operative Details; f眉r die tats盲chlichen Zahlen und Erl盲uterungen ist Exhibit 99.1 zu konsultieren. Die Stammaktien des Registranten werden unter dem K眉rzel TRML am Nasdaq Global Select Market gehandelt, und in dieser Einreichung sind keine weiteren wesentlichen Transaktionen oder Finanztabellen enthalten.
- None.
- None.
Insights
TL;DR: The 8-K notifies investors a press release with Q2 2025 results was furnished; the filing itself provides no financial detail to evaluate performance.
The filing is a routine disclosure that alerts the market a press release exists with business highlights and quarter-end results. Because the 8-K does not include revenue, earnings, cash flow, or guidance, there is insufficient information here to assess financial performance or trend direction. The explicit statement that the material is "furnished, not filed" limits legal exposure and signals readers must review Exhibit 99.1 and the Inline XBRL cover for substantive numbers and disclosures.
TL;DR: Procedurally standard: company furnished a press release and noted it is not incorporated by reference; no governance or material control signals present.
This 8-K follows common practice by furnishing a press release and attaching an XBRL cover. The filing emphasizes the distinction between "furnished" and "filed," which is important for liability and incorporation-by-reference considerations. There are no disclosures here about executive changes, related-party transactions, or material agreements, so from a governance perspective the document is neutral and administrative rather than indicative of corporate control or structural changes.
Tourmaline Bio, Inc. ha presentato un Current Report on Form 8-K in cui comunica di aver diffuso un comunicato stampa con i principali eventi aziendali e i risultati finanziari relativi al trimestre chiuso il 30 giugno 2025. Il comunicato 猫 allegato come Exhibit 99.1 e una pagina di copertina Inline XBRL 猫 inclusa come Exhibit 104. La societ脿 precisa che queste informazioni sono fornite, non depositate, pertanto non sono soggette alle responsabilit脿 previste dalla Sezione 18 e non vengono incorporate per riferimento in altri documenti salvo esplicita indicazione.
L'8-K in s茅 non contiene dati finanziari numerici n茅 dettagli operativi; per i valori e la descrizione occorre consultare l'Exhibit 99.1. Le azioni ordinarie del registrante sono negoziate con il simbolo TRML sul Nasdaq Global Select Market e nel presente documento non sono incluse altre operazioni rilevanti o tabelle finanziarie.
Tourmaline Bio, Inc. present贸 un Current Report on Form 8-K en el que anuncia la emisi贸n de un comunicado de prensa con los aspectos m谩s relevantes del negocio y los resultados financieros del trimestre concluido el 30 de junio de 2025. El comunicado se adjunta como Exhibit 99.1 y se incluye una portada Inline XBRL como Exhibit 104. La compa帽铆a indica que esta informaci贸n se proporciona, no se presenta, por lo que no est谩 sujeta a las responsabilidades de la Secci贸n 18 y no se incorpora por referencia en otros documentos salvo que se indique expresamente.
El 8-K en s铆 no contiene cifras num茅ricas ni detalles operativos; los lectores deben consultar el Exhibit 99.1 para los datos y la narrativa. Las acciones ordinarias del registrante cotizan bajo el s铆mbolo TRML en el Nasdaq Global Select Market y en este informe no se incluyen otras transacciones materiales ni tablas financieras.
Tourmaline Bio, Inc.電� Current Report on Form 8-K毳� 鞝滌稖頃橃棳 2025雲� 6鞗� 30鞚茧 膦呺霅� 攵勱赴鞚� 欤检殧 靷梾 雮挫毄 氚� 鞛 瓴瓣臣毳� 鞎岆Μ電� 氤措弰鞛愲毳� 氚滍憸頄堧嫟瓿� 氚濏様鞀惦媹雼�. 氤措弰鞛愲電� Exhibit 99.1搿� 觳秬霅橃柎 鞛堨溂氅� Inline XBRL 響滌電� Exhibit 104搿� 韽暔霅橃柎 鞛堨姷雼堧嫟. 須岇偓電� 鞚� 鞝曤炒臧� 鞝滌稖霅� 瓴冹澊 鞎勲媹霛� 鞝滉车霅� 瓴�鞚措澕瓿� 氇呾嫓頃橃棳 靹轨厴 18鞐� 霐半ジ 毂呾瀯鞚� 雽�靸侅澊 鞎勲媹氅�, 氇呾嫓鞝侅溂搿� 鞏戈笁霅橃 鞎婋姅 頃� 雼るジ 靹滊鞐� 彀胳“搿� 韱淀暕霅橃 鞎婋姅雼り碃 頃╇媹雼�.
頃措嫻 8-K 鞛愳泊鞐愲姅 靾橃箻鞝� 鞛 雿办澊韯半倶 鞖挫榿 靹鸽秬靷暛鞚� 韽暔霅橃柎 鞛堨 鞎婌溂氙�搿� 鞁れ牅 靾橃箻鞕� 靹る獏鞚� Exhibit 99.1鞚� 頇曥澑頃挫暭 頃╇媹雼�. 霌彪須岇偓鞚� 氤错喌欤茧姅 TRML鞚措澕電� 鞁臣搿� Nasdaq Global Select Market鞐� 靸侅灔霅橃柎 鞛堨溂氅�, 鞚� 鞝滌稖靹滊鞐愲姅 旮绊儉 欷戩殧頃� 瓯半灅雮� 鞛響滉皜 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟.
Tourmaline Bio, Inc. a fourni un Current Report on Form 8-K indiquant qu'elle a publi茅 un communiqu茅 de presse pr茅sentant les faits marquants et les r茅sultats financiers du trimestre clos le 30 juin 2025. Le communiqu茅 est joint en tant que Exhibit 99.1 et une page de couverture Inline XBRL est incluse en tant que Exhibit 104. La soci茅t茅 pr茅cise que ces informations sont fournies, non d茅pos茅es, elles ne sont donc pas soumises aux responsabilit茅s pr茅vues par la Section 18 et ne sont pas incorpor茅es par r茅f茅rence dans d'autres documents, sauf indication expresse.
Le 8-K lui-m锚me ne contient pas de donn茅es chiffr茅es ni de d茅tails op茅rationnels聽; il convient de consulter l'Exhibit 99.1 pour les chiffres et le commentaire. Les actions ordinaires de l'茅metteur se n茅gocient sous le symbole TRML sur le Nasdaq Global Select Market et aucun autre acte significatif ni aucune table financi猫re n'est inclus dans ce d茅p么t.
Tourmaline Bio, Inc. hat einen Current Report on Form 8-K eingereicht und darin eine Pressemitteilung mit Gesch盲ftshighlights und Finanzzahlen f眉r das am 30. Juni 2025 endende Quartal ver枚ffentlicht. Die Pressemitteilung ist als Exhibit 99.1 beigef眉gt, eine Inline-XBRL-Titelseite ist als Exhibit 104 enthalten. Das Unternehmen stellt klar, dass diese Informationen bereitgestellt, nicht eingereicht werden, weshalb sie nicht den Haftungsregelungen nach Abschnitt 18 unterliegen und nicht ohne ausdr眉ckliche Angabe in andere Einreichungen 眉bernommen werden.
Der 8-K selbst enth盲lt keine numerischen Finanzdaten oder operative Details; f眉r die tats盲chlichen Zahlen und Erl盲uterungen ist Exhibit 99.1 zu konsultieren. Die Stammaktien des Registranten werden unter dem K眉rzel TRML am Nasdaq Global Select Market gehandelt, und in dieser Einreichung sind keine weiteren wesentlichen Transaktionen oder Finanztabellen enthalten.
FAQ
What did Tourmaline Bio (TRML) disclose in this 8-K?
Are the financial results in this 8-K filed with the SEC?
Where can I find the actual financial figures for Q2 2025?
What is Tourmaline Bio's ticker and exchange?
Does this filing disclose any material transactions or executive changes?
